James Jungkue Lee, Bridge Biotherapeutics CEO (LinkedIn)
February 21, 2023 10:58 AM EST
R&D

Bridge Bio­ther­a­peu­tic­s' ul­cer­a­tive col­i­tis drug fails Phase II tri­al; biotech plans to push for­ward

Lei Lei Wu

News Reporter

South Ko­re­an biotech Bridge Bio­ther­a­peu­tics an­nounced Mon­day that its mid-stage tri­al for an ul­cer­a­tive col­i­tis drug failed.

The biotech said that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times